{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-22-000014","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.667129+00:00","generated_at":"2026-06-26T00:23:17.322235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY","bullets":["Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.","Net income $239.9M (diluted EPS $5.03) vs $28.3M ($0.61) in Q1 2021; earnings surge primarily due to strong revenue and lower R&D spend.","Tyvaso DPI NDA under FDA review with decision expected in May 2022; company awaits outcome of citizen petition and inspection issues.","Phase 3 TETON 1 & 2 studies for IPF, PERFECT for PH-COPD, and ADVANCE trials for ralinepag are enrolling or commencing.","Orenitram revenue grew 14% YoY to $82.8M on volume and price; Remodulin flat at $131.7M with U.S. decline offset by international orders."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-22-000014","json":"https://secwatch.observer/filing/0001082554-22-000014.json","markdown":"https://secwatch.observer/filing/0001082554-22-000014.md","text":"https://secwatch.observer/filing/0001082554-22-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/0001082554-22-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/uthr-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:23:17.322235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}